Recombinant multi-species SLC35B2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC35B2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Sulfotransferases (e.g., SULT4A1; MIM 608359) use an activated form of sulfate, 3-prime-phosphoadenosine 5-prime-phosphosulfate (PAPS), as a common sulfate donor for sulfation of glycoproteins, proteoglycans, and glycolipids in the endoplasmic reticulum and Golgi apparatus. SLC35B2 is located in the microsomal membrane and transports PAPS from the cytosol, where it is synthesized, into the Golgi lumen (Kamiyama et al., 2003 [PubMed 12716889]).[supplied by OMIM, Mar 2008]
The Alternative Names of target: 1110003M08Rik,Adenosine 3'-phospho 5'-phosphosulfate transporter 1,Dsm-1,HLD26,PAPS transporter 1,PAPST1,Putative MAPK-activating protein PM15,Putative NF-kappa-B-activating protein 48,SLC35B2,SLL,Slc35b1,Slc35b2,Solute carrier family 35 member B2,UGTrel4
Go
to SLC35B2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP1706-Ag-1/ GM-Tg-hg-IP1706-Ag-2 | Human SLC35B2 protein | Human |
| GM-Tg-rg-IP1706-Ag-1/ GM-Tg-rg-IP1706-Ag-2 | Rat SLC35B2 protein | Rat |
| GM-Tg-mg-IP1706-Ag-1/ GM-Tg-mg-IP1706-Ag-2 | Mouse SLC35B2 protein | Mouse |
| GM-Tg-cynog-IP1706-Ag-1/ GM-Tg-cynog-IP1706-Ag-2 | Cynomolgus/Rhesus macaque SLC35B2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP1706-Ag-1/ GM-Tg-felg-IP1706-Ag-2 | Feline SLC35B2 protein | Feline |
| GM-Tg-cang-IP1706-Ag-1/ GM-Tg-cang-IP1706-Ag-2 | Canine SLC35B2 protein | Canine |
| GM-Tg-bovg-IP1706-Ag-1/ GM-Tg-bovg-IP1706-Ag-2 | Bovine SLC35B2 protein | Bovine |
| GM-Tg-equg-IP1706-Ag-1/ GM-Tg-equg-IP1706-Ag-2 | Equine SLC35B2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP1706-Ag-1/ GM-Tg-hg-IP1706-Ag-2;
GM-Tg-rg-IP1706-Ag-1/ GM-Tg-rg-IP1706-Ag-2;
GM-Tg-mg-IP1706-Ag-1/ GM-Tg-mg-IP1706-Ag-2; GM-Tg-cynog-IP1706-Ag-1/ GM-Tg-cynog-IP1706-Ag-2; GM-Tg-felg-IP1706-Ag-1/ GM-Tg-felg-IP1706-Ag-2; GM-Tg-cang-IP1706-Ag-1/ GM-Tg-cang-IP1706-Ag-2; GM-Tg-bovg-IP1706-Ag-1/ GM-Tg-bovg-IP1706-Ag-2; GM-Tg-equg-IP1706-Ag-1/ GM-Tg-equg-IP1706-Ag-2 |
| Products Name | SLC35B2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | SLC35B2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLC35B2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.